A carregar...
Immunotherapies targeting CD38 in Multiple Myeloma
Recently, the monoclonal antibody daratumumab was approved as a single agent for the treatment of patients with relapsed/refractory Multiple Myeloma (MM). Daratumumab is an antibody targeting surface molecule CD38 on myeloma cells and the agent is already widely being used based on its good tolerabi...
Na minha lista:
| Publicado no: | Oncoimmunology |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Taylor & Francis
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5139636/ https://ncbi.nlm.nih.gov/pubmed/27999737 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2016.1217374 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|